Kadmon Holdings Llc (KDMN)

9.5  +0.02 (+0.21%)

After market: 9.49 -0.01 (-0.11%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to KDMN. KDMN was compared to 588 industry peers in the Biotechnology industry. Both the profitability and financial health of KDMN have multiple concerns. While showing a medium growth rate, KDMN is valued expensive at the moment.



0

1. Profitability

1.1 Basic Checks

In the past year KDMN has reported negative net income.

1.2 Ratios

Industry RankSector Rank
ROA -35.84%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM -6354.85%
PM (TTM) -5955.81%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

2

2. Health

2.1 Basic Checks

KDMN has more shares outstanding than it did 1 year ago.
KDMN has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of 1.06, we must say that KDMN is in the distress zone and has some risk of bankruptcy.
A Debt/Equity ratio of 6.96 is on the high side and indicates that KDMN has dependencies on debt financing.
Industry RankSector Rank
Debt/Equity 6.96
Debt/FCF N/A
Altman-Z 1.06
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 9.46 indicates that KDMN has no problem at all paying its short term obligations.
KDMN has a Quick Ratio of 9.46. This indicates that KDMN is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 9.46
Quick Ratio 9.46

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 28.72% over the past year.
The Revenue for KDMN has decreased by -84.20% in the past year. This is quite bad
KDMN shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -25.33% yearly.
EPS 1Y (TTM)28.72%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-5.88%
Revenue 1Y (TTM)-84.2%
Revenue growth 3Y-12.23%
Revenue growth 5Y-25.33%
Revenue growth Q2Q-56.22%

3.2 Future

The Earnings Per Share is expected to grow by 2.19% on average over the next years.
The Revenue is expected to grow by 153.65% on average over the next years. This is a very strong growth
EPS Next Y-11.43%
EPS Next 2Y0.07%
EPS Next 3Y12.98%
EPS Next 5Y2.19%
Revenue Next Year-3.81%
Revenue Next 2Y164.74%
Revenue Next 3Y157.81%
Revenue Next 5Y153.65%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

0

4. Valuation

4.1 Price/Earnings Ratio

KDMN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KDMN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -13.51

4.3 Compensation for Growth

A more expensive valuation may be justified as KDMN's earnings are expected to grow with 12.98% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.07%
EPS Next 3Y12.98%

0

5. Dividend

5.1 Amount

No dividends for KDMN!.
Industry RankSector Rank
Dividend Yield N/A

Kadmon Holdings Llc

NASDAQ:KDMN (11/8/2021, 7:24:43 PM)

After market: 9.49 -0.01 (-0.11%)

9.5

+0.02 (+0.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.63B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -35.84%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM -6354.85%
PM (TTM) -5955.81%
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 6.96
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 9.46
Quick Ratio 9.46
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)28.72%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-11.43%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-84.2%
Revenue growth 3Y-12.23%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y